Skip To Main Content
Publications icon


Visit to browse a listing of published scientific literature about Vabysmo®.

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials
Heier JS et al. Lancet 2022 Feb;399(10326):729-740.

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
Wykoff CC, Abreu F, Adamis AP, et al. Lancet 2022 Feb 19;399:741-755.

Scientific congresses icon

Scientific Congresses

Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at

September 30-October 3, 2022

October 16-19, 2022

October 26-29, 2022

November 2-5, 2022

Clinical trials icon

Clinical Trials

Find information about active clinical research for Vabysmo® at and information about our research at Genentech Clinical Trials.

Additional resources icon

Additional Resources

For additional information or assistance regarding Vabysmo®, use the links below.

Connect with a Medical Science Liaison

Browse the Genentech Medical Information Library

Ophthalmology at Genentech

Ophthalmology at Roche